Resultats de la cerca

Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression per Martina Sanlorenzo, Igor Vujic, Adil Daud, Alain P. Algazi, Matthew A. Gubens, Sara Alcántara Luna, Kevin Lin, Pietro Quaglino, Klemens Rappersberger, Susana Ortiz‐Urda

Obtenir text complet Obtenir text complet

Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy per Keishi Adachi, Koji Tamada

Obtenir text complet Obtenir text complet

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma per Reinhard Dummer, Adil Daud, Igor Puzanov, Omid Hamid, Dirk Schadendorf, Caroline Robert, Jacob Schachter, Anna C. Pavlick, René González, F. Stephen Hodi, Lee D. Cranmer, Christian U. Blank, Steven O’Day, Paolo A. Ascierto, April K.S. Salama, Nicole Xiaoyun Li, Wei Zhou, Joy Lis, Scot Ebbinghaus, Peter Kang, Antoni Ribas

Obtenir text complet Obtenir text complet

Managing Immune Checkpoint-Blocking Antibody Side Effects per Michael A. Postow

Obtenir text complet Obtenir text complet

PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV per Diwakar Davar, Melissa Wilson, Chelsea Pruckner, John M. Kirkwood

Obtenir text complet Obtenir text complet

Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes per C. Gaudy, C. Clévy, S. Monestier, Noémie Dubois, Yanis Préau, S. Mallet, M.‐A. Richard, Jean‐Jacques Grob, René Valero, Sophie Béliard

Obtenir text complet

Prospects of immune checkpoint modulators in the treatment of glioblastoma per Matthias Preusser, Michael Lim, David A. Hafler, David A. Reardon, John H. Sampson

Obtenir text complet

A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor per Anne Lynn S. Chang, Jinah Kim, Richard Luciano, Loretta Sullivan-Chang, A. Dimitrios Colevas

Obtenir text complet Obtenir text complet

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial per Antoni Ribas, Igor Puzanov, Reinhard Dummer, Dirk Schadendorf, Omid Hamid, Caroline Robert, F. Stephen Hodi, Jacob Schachter, Anna C. Pavlick, Karl D. Lewis, Lee D. Cranmer, Christian U. Blank, Steven O’Day, Paolo A. Ascierto, April K.S. Salama, Kim Margolin, Carmen Loquai, Thomas Eigentler, Tara C. Gangadhar, Matteo S. Carlino, Sanjiv S. Agarwala, Stergios J. Moschos, Jeffrey A. Sosman, Simone M. Goldinger, Ronnie Shapira‐Frommer, René González, John M. Kirkwood, Jedd D. Wolchok, Alexander M.M. Eggermont, Xiaoyun Li, Wei Zhou, Adriane M Zernhelt, Joy Lis, Scot Ebbinghaus, S. Peter Kang, Adil Daud

Obtenir text complet Obtenir text complet

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma per Jason J. Luke, Patrick A. Ott

Obtenir text complet Obtenir text complet

PD-1 Blockers per Jedd D. Wolchok

Obtenir text complet

Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy per Jennifer A. Lo, David E. Fisher, Keith T. Flaherty

Obtenir text complet

Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy per Anna Niezgoda, Piotr Niezgoda, Rafał Czajkowski

Obtenir text complet Obtenir text complet

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency per Dung T. Le, Jennifer N. Uram, Hao Wang, Bjarne R. Bartlett, Holly Kemberling, Aleksandra Eyring, Andrew D. Skora, Brandon Luber, Nilofer S. Azad, Dan Laheru, Barbara Biedrzycki, Ross C. Donehower, Atif Zaheer, George A. Fisher, Todd S. Crocenzi, James J. Lee, Steven M. Duffy, Richard M. Goldberg, Albert de la Chapelle, Minori Koshiji, Feriyl Bhaijee, Thomas Huebner, Ralph H. Hruban, Laura D. Wood, Nathan Cuka, Drew M. Pardoll, Nickolas Papadopoulos, Kenneth W. Kinzler, Shibin Zhou, Toby C. Cornish, Janis M. Taube, Robert A. Anders, James R. Eshleman, Bert Vogelstein, Luis A. Díaz

Obtenir text complet Obtenir text complet

Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Melanoma per Douglas B. Johnson, Igor Puzanov, Mark C. Kelley

Obtenir text complet

Melanoma of the oral cavity: pathogenesis, dermoscopy, clinical features, staging and management per Olga Warszawik‐Hendzel, Monika Słowińska, Małgorzata Olszewska, Lidia Rudnicka

Obtenir text complet

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma per Kathleen M. Mahoney, Gordon J. Freeman, David F. McDermott

Obtenir text complet

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer per Edward B. Garon, Naiyer A. Rizvi, Rina Hui, Natasha B. Leighl, Ani Sarkis Balmanoukian, Joseph P. Eder, Amita Patnaik, Charu Aggarwal, Matthew A. Gubens, Leora Horn, Enric Carcereny, Myung‐Ju Ahn, Enriqueta Felip, Jong-Seok Lee, Matthew D. Hellmann, Omid Hamid, Jonathan W. Goldman, Jean‐Charles Soria, Marisa Dolled‐Filhart, Ruth Z. Rutledge, Jin Zhang, Jared Lunceford, Reshma Rangwala, Gregory M. Lubiniecki, Charlotte Roach, Kenneth Emancipator, Leena Gandhi

Obtenir text complet Obtenir text complet

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma per Heinz Läubli, Cathrin Balmelli, Matthias Bossard, Otmar Pfister, Kathrin Glatz, Alfred Zippelius

Obtenir text complet Obtenir text complet

Antibody-based therapeutics to watch in 2011 per Janice M. Reichert

Obtenir text complet Obtenir text complet